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Abstract
The amyloid protein aggregation associated with diseases such as Alzheimer’s, Parkinson’s, and 
type II diabetes (among many others), features a bewildering variety of β-sheet-rich structures in 
transition from native proteins to ordered oligomers and fibers. The variation in the amino acid 
sequences of the β-structures presents a challenge to developing a model system of β-sheets for the 
study of various amyloid aggregates. Here we introduce a family of robust β-sheet macrocycles 
that can serve as a platform to display a variety of heptapeptide sequences from different amyloid 
proteins. We have tailored these amyloid β-sheet mimics (ABSMs) to antagonize aggregation of 
various amyloid proteins, thereby reducing the toxicity of amyloid aggregates. We describe the 
structures and inhibitory properties of ABSMs containing amyloidogenic peptides from Aβ 
associated with Alzheimer’s disease, β2-microglobulin associated with dialysis-related 
amyloidosis, α-synuclein associated with Parkinson’s disease, islet amyloid polypeptide 
associated with type II diabetes, human and yeast prion proteins, and Tau, which forms 
neurofibrillary tangles.
Introduction
Amyloid aggregation is associated with many intractable protein aggregation diseases, 
notably including Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, type II 
diabetes, and prion diseases1–3. Amyloid fibrils with characteristic highly ordered cross-β 
structures are the ultimate products of amyloid aggregation. More than 30 proteins have 
been linked to amyloidogenesis and they exhibit enormous variations in sequences and 
polymorphic fibril structures1,4–6. Fibril formation of a given polypeptide, however, greatly 
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depends on its specific residue order7,8. Crystallographic structures of amyloidlike fibrils 
formed by amyloidogenic peptide fragments suggest that the formation of highly-ordered 
parallel or antiparallel β-sheets and a steric-zipper interface between β-sheets are two 
essential elements for amyloid fibril formation9,10.
While amyloid fibrils are the most visible evidence of pathology, soluble oligomers are 
proving to be more important in amyloid toxicity11,12. Although increasing evidence shows 
that these transient, unstable structures are rich in β-sheets, their dynamic and polymorphic 
properties make amyloid oligomers difficult to study at the atomic level13–15. Additional 
tools are needed to study amyloid oligomers and aggregation and to shed light on controlling 
these processes.
β-Sheet mimics that can display amyloid β-strands provide a means to study amyloid 
oligomers and aggregation. We previously introduced 42-membered ring macrocyclic β-
sheets containing pentapeptide fragments from amyloid-β peptide (Aβ) and tau protein (Tau) 
to mimic amyloidlike β-sheets and shed a light on the structures of transient amyloid 
oligomers16,17. We have also used these macrocyclic β-sheets to inhibit aggregation of the 
peptide Ac-VQIVYK-NH2 (AcPHF6) derived from Tau to provide insights into the 
aggregation process18.
The development of a robust chemical model of β-sheets that can tolerate a variety of amino 
acid sequences has been challenging because amyloidogenic sequences vary enormously 
and because folding of β-sheet mimics largely depends on the amino acid sequence1,19. In 
this paper, we introduce a new class of β-sheet macrocycles that can tolerate a wide range of 
amino acid sequences from amyloid proteins and still fold into β-sheet structures. We call 
these macrocycles amyloid β-sheet mimics (ABSMs).
ABSM 1 is a 54-membered ring and comprises a heptapeptide β-strand (the upper strand), 
one Hao unit flanked by two dipeptides (the lower strand), and two δ-linked ornithine (δOrn) 
turns (Figure 1a). The “upper” β-strand of ABSM 1 incorporates different heptapeptide 
fragments from Aβ, Tau, yeast Sup35 prion protein (Sup35), human prion protein (hPrP), 
human β2-microglobulin (hβ2M), human α-synuclein (hαSyn), and human islet amyloid 
polypeptide (hIAPP). Hao is a tripeptide β-strand mimic that not only serves as a template 
for intramolecular hydrogen bonding but also minimizes the exposed hydrogen-bonding 
functionality of the “lower” strand20. This structural design of Hao helps prevent ABSMs 1 
from aggregating in solution to form an infinite network of in-register β-sheets; instead, 
ABSMs 1 dimerize and then further self-assemble into oligomers. The “upper” and “lower” 
strands of ABSM 1 are connected by two δOrn β-turn mimics21.
We envisioned that ABSM 1 would fold well because it is conformationally constrained by 
cyclicity and has a Hao template to promote intramolecular hydrogen bonding and two δOrn 
β-turn mimics to promote turn formation. We also envisioned that four pairs of side chains 
(R1–R11, R2–R10, R6–R9, and R7–R8) would provide stabilizing transannular interactions. 
We anticipated that the flexibility of the dipeptides flanking Hao in the “lower” strand 
would better accommodate the flatness of the Hao template and thus minimize the kinks in 
the β-strands that we had previously observed in the 42-membered ring macrocycles17.
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We designed ABSMs 1 to display exposed heptapeptide β-strands so that these β-strands can 
recognize and bind their parent amyloid proteins (Figure 1b). We envisioned recognition 
between ABSMs 1 and their parent amyloid proteins to take place through the β-sheet 
interactions observed in amyloid aggregation.
Here, we present structural studies of these ABSMs 1 and describe their effect upon amyloid 
aggregation and toxicity.
Results
1. Design of Amyloid β-Sheet Mimics 1
To test the folding of ABSMs 1, we selected 16 amyloidogenic heptapeptide β-strands from 
seven β-sheet-rich amyloid proteins for positions 1–7 in the “upper” strands (Table 1). 
ABSMs 1a–g contain heptapeptide sequences from two important hydrophobic and fibril-
forming regions of Aβ associated with Alzheimer’s disease, residues 16–23 and 29–405, 22. 
ABSMs 1a–d and f contain native heptapeptide sequences, while ABSMs 1e and 1g are 
G33F and G37F mutants, in which the aromatic residue across from Hao promotes better 
folding16. ABSM 1h contains residues 7–13 from Sup35, which has been widely used as a 
model to study amyloid formation9. ABSM 1i contains residues 116–122 from hPrP, which 
is the infectious agent of prion diseases23. ABSM 1j contains residues 305–311 from Tau, 
which forms neurofibrillary tangles24. ABSM 1k–m contain residues 62–68 and 63–69 from 
hβ2M associated with dialysis-related amyloidosis25. ABSMs 1n and 1o contain residues 
69–75 and 75–81 from hαSyn associated with Parkinson’s disease26. ABSMs 1p and 1q 
contain residues 11–17 and 26–32 from hIAPP associated with type II diabetes27. We chose 
polar and hydrophobic residues at positions 8–11 in the “lower” strands of ABSMs 1 to 
promote solubility in water and to increase hydrophobic residues that favor β-sheet 
formation.
2. Synthesis of Amyloid β-Sheet Mimics 1
ABSMs 1 were prepared by synthesizing the corresponding protected linear peptides, 
followed by solution-phase cyclization and deprotection28. The protected linear peptide 
precursors were synthesized on 2-chlorotrityl chloride resin by conventional Fmoc-based 
solid-phase peptide synthesis. Macrocyclization was typically performed using HCTU and 
N,N-diisopropylethylamine in DMF at ca. 0.5 mM concentration. The ABSMs 1 were 
isolated in ca. 20–30% overall yield after HPLC purification and lyophilization. Each 
synthesis produces tens of milligrams of ABSMs 1 as fluffy white solids. (For details, see 
the Supplementary Information Text.)
3. X-Ray Crystallographic Studies of Amyloid β-Sheet Mimic 1r
X-ray crystallography of ABSM 1r validates the design of ABSMs 1 (Figure 2). ABSM 1r 
is a homologue of ABSM 1d in which the Tyr residue in the “lower” strand is replaced with 
4-bromophenylalanine for crystallographic phase determination. ABSM 1r adopts a β-sheet 
structure in which the “upper” and “lower” strands are intramolecularly hydrogen-bonded to 
form eight hydrogen bonds (Figure 2a). The two δOrn residues of ABSM 1r fold into β-turn 
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like conformations, Hao mimics a tripeptide β-strand, and the “upper” strand displays an 
exposed heptapeptide β-sheet edge.
ABSM 1r forms a dimer in the crystal lattice in which the two recognition β-strands come 
together in an antiparallel β-sheet fashion (Figure 2b). The β-strands of the dimerization 
interface are shifted out of register, forming only six hydrogen bonds instead of the eight 
that would form through in-register contact.
The dimers stack in the crystal lattice, with hydrophobic contacts between the layers of the 
stack. The Ile, Leu, and Val, at positions 3, 5, and 7 on the “top” face of the dimer pack 
together in one set of hydrophobic contacts “above” the dimer, while the Met and Phe at 
positions 6 and 9 on the “bottom” face of the dimer pack together in another set of 
hydrophobic contacts “below” the dimer (Figures 2c and 2d). The hydrophobic contacts 
between the dimer layers appear to be important in the crystallization and supramolecular 
assembly of ABSM 1r and may explain the formation of the out-of-register interface within 
the dimer.
4. 1H NMR Studies of Amyloid β-Sheet Mimics 1
1H NMR studies of ABSMs 1a–q in D2O solution further validate the design of ABSMs 1 
and establish that ABSMs 1 generally adopt folded β-sheet structures in solution. The 1H 
NMR spectra of ABSMs 1 show sharp, disperse resonances at submillimolar and low 
millimolar concentrations in D2O solution, suggesting ABSMs 1 to be non-aggregating in 
water. Antiparallel β-sheets have close contacts between the α-protons of the non-hydrogen-
bonded pairs of amino acids, which generally give strong interstrand NOE cross-peaks 
(NOEs). In ABSMs 1, these close contacts should involve the α-protons of residues 2 and 10 
(2–10) and residues 6 and 9 (6–9). There should also be homologous contacts involving the 
α-proton of residue 4 and H6 of Hao (4-Hao6) and the α- and pro-S δ-protons of the δOrn 
turns (Orn α-δS). Table 1 illustrates these contacts.
All ABSMs, except 1h, 1i, and 1l, exhibit most of these key NOEs (Table 1). ABSMs 1a–e, 
1g, 1j, 1k, and 1m–q show strong 2–10, 6–9, 4-Hao6, and Ornα-δS NOEs and thus exhibit 
good folding. ABSM 1f shows strong Ornα-δS and 2–10 NOEs and a weak 4-Hao6 NOE and 
thus exhibits moderate folding. ABSMs 1h, 1i, and 1l show only Ornα-δS NOEs and thus 
exhibit weak folding. Although the lack of the interstrand NOEs indicates poor folding of 
ABSMs 1h, 1i, and 1l, the Ornα-δS NOEs suggest that their δOrn residues fold at least 
partially into a β-turn like conformation. Table 1 summarizes the observed key NOEs and 
the folding of ABSMs 1.
5. Inhibition of Amyloid Aggregation by Amyloid β-Sheet Mimics 1
Thioflavin T (ThT) fluorescence assays and transmission electron microscopy (TEM) 
studies show that the ABSMs containing amyloidogenic sequences can inhibit aggregation 
of amyloid proteins. We studied inhibition of Aβ40 and Aβ42 aggregation by ABSM 1a, 
inhibition of hβ2M aggregation by ABSM 1m, and inhibition of truncated human α-
synuclein (hαSyn1–100) aggregation by ABSM 1o.
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ThT fluorescence assays show that ABSMs 1a, 1m, and 1o effectively delay aggregation of 
their parent proteins at sub-stoichiometric concentrations in a dose-dependent manner 
(Figures 3a–d). ABSM 1a delays Aβ40 and Aβ42 aggregation by 280% and 350% 
respectively at 0.2 equivalents and by 430% and 600% at 0.5 equivalents (Figures 3a and 
3b). Although ThT fluorescence assays show that Aβ aggregation exhibits comparable lag 
times at 0.5 and 1.0 equivalents of ABSM 1a, the growth phases of the aggregation are 
much slower at 1.0 equivalent than at 0.5 equivalents. (* in Figures 3a and 3b. For details, 
see Figures S1 and S2.) ABSM 1m delays hβ2M aggregation by 160% at 0.2 and 0.5 
equivalents and by 340% at 1.0 equivalent (Figure 3c). ABSM 1o delays hαSyn1–100 
aggregation by 150% at 0.2 equivalents (Figure 3d). Although hαSyn1–100 aggregation 
exhibits longer lag times with 0.5 and 1.0 equivalents of ABSM 1o than with 0.2 
equivalents, some runs showed complete suppression of aggregation, while other runs 
showed typical sigmoidal curves. Because of this scatter in the data, the precise lag times are 
not reported. (* in Figure 3d. For details, see Figure S4.) TEM studies of samples taken 
directly from the ThT assays show that Aβ, hβ2M, and hαSyn1–100 form fibrils without 
ABSMs and do not form fibrils with ABSMs (1.0 equivalent) during the delayed lag time 
(Figures 3eh).
Aβ has been shown to cross-interact with different amyloidogenic proteins containing 
similar primary sequences29–31. To investigate cross-interaction of Aβ with ABSMs, we 
compared the interaction of Aβ with ABSM 1a to that with ABSM 1m, which has a closely 
homologous sequence, and to that with ABSM 1o, which does not (Figure S5). ThT 
fluorescence assays show that ABSM 1m inhibits Aβ aggregation, like ABSM 1a, while 
ABSM 1o has little or no inhibitory effect (Figure S5). This result suggests that structurally 
homologous ABSMs can not only interact with their parent amyloid proteins but can also 
cross interact with different amyloid proteins.
To further investigate the effect of sequence on inhibition, we compared the interaction of 
ABSM 1a with Aβ40 to that of ABSMs 1b, 1c, 1d, and 1f with Aβ40. ThT fluorescence 
assays show that ABSM 1b is effective against Aβ40 aggregation, while ABSMs 1c, 1d, and 
1f cause little or no inhibition (Figure S6). The inhibition of Aβ40 aggregation by both 
ABSMs 1a and 1b indicates that the central hydrophobic sequence Aβ17–21 is critical to the 
activity of ABSMs against Aβ40 aggregation. This result supports the role of Aβ17–21 in Aβ 
aggregation and suggests that strong interaction of this sequence in these ABSMs with that 
of the Aβ oligomers delays Aβ aggregation22, 32.
6. Detoxification of Aβ by Amyloid β-Sheet Mimic 1a
Cell viability (MTT) assays establish that ABSM 1a reduces the toxicity of Aβ40 and Aβ42 
in PC-12 cells (Figure 4) and that ABSMs 1a, 1m, and 1o exhibit little or no toxicity (Figure 
S9). We examined the effect of ABSM 1a on the toxicity of Aβ40 and Aβ42, because ABSM 
1a exhibits the best inhibitory activity among those studied. We first incubated Aβ 
monomers (5μM) without ABSM 1a to allow Aβ oligomers and fibrils to form. The 
resulting Aβ mixtures were directly used in cell viability assays. These assays show that the 
Aβ40 and Aβ42 preincubated without ABSM 1a kills 42% and 46% of the PC-12 cells 
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respectively, relative to controls in which the cells are incubated in only PBS buffer 
solutions (Figure 4).
Cell viability assays further establish that preincubation of Aβ with ABSM 1a rescues the 
cells in a dose-dependent manner. Preincubation of Aβ40 and Aβ42 with 0.2 equivalents of 
ABSM 1a reduces the death of PC-12 to 29% and 38% respectively, while preincubation 
with 1.0 equivalent reduces cell death to 27% and 30% and preincubation with 5 equivalents 
reduces cell death to 14% and 6%. The rescue of these neuron like cells by ABSM 1a 
suggests that ABSMs may reduce the production of toxic amyloid oligomers or bind the 
oligomers and reduce their toxicity.
Discussion
Amyloid β-sheet mimics 1 provide a unique tool with which to elucidate the process of 
amyloid aggregation. Although many of the details of amyloid aggregation still remain 
unclear, nucleation-dependent polymerization, in which seeding to form a β-structured 
nucleus is the rate-determining step, is widely accepted1, 22. Based on the nucleation-
dependent polymerization, we propose a model for the potent inhibition of Aβ aggregation 
by ABSM 1a. In this model, ABSM 1a binds early β-structured oligomers and blocks Aβ 
nucleation (Figure 5a). Without ABSM 1a, the unstructured monomer forms β-structured 
oligomers which, in the rate-determining step, go on to form a β-structured nucleus that 
ultimately assembles to form cross-β fibrils. The solid line in Figure 5a illustrates this 
pathway. ABSM 1a creates a new aggregation pathway for the early β-structured oligomers. 
In this pathway, ABSM 1a binds the β-structured oligomers to form Aβ-oligomer-ABSM-1a 
complexes and blocks the Aβ oligomer-to-nucleus transition. The dashed line in Figure 5a 
illustrates this pathway.
It is significant that ABSM 1a substantially delays the aggregation of Aβ at sub-
stoichiometric concentrations (as low as 1 μM), e.g. 0.05 equivalents of ABSM 1a per 
equivalent of Aβ (Figure S2), while simple linear peptide fragments derived from Aβ 
generally show substantial inhibitory effects at stoichiometric or greater concentrations33,34. 
This observation suggests that ABSM 1a binds a larger oligomer, not the monomer or a 
smaller oligomer, such as a dimer, trimer, or tetramer. ABSM 1a binds the early β-structured 
oligomers more strongly than the unstructured monomers bind oligomers, because the 
recognition β-strand of ABSM 1a is preorganized. This preorganization thus promotes 
formation of Aβ-oligomer-ABSM-1a complexes. The complexation may occur through 
edge-to-edge interactions between the hydrogen-bonding edge of ABSM 1a and exposed 
hydrogen-bonding groups of the Aβ oligomers and through face-to-face hydrophobic 
interactions between ABSM 1a and the hydrophobic surfaces of the Aβ oligomers. These 
types of interactions should take place between the hydrophobic sequence Aβ17–21 of ABSM 
1a and that of the Aβ oligomers, as observed in the amyloid-related oligomers containing the 
pentapeptide sequence LVFFA shown in Figure 5b and the amyloidlike fibrils from the 
hexapeptide KLVFFA shown in Figure 5c. Similar interactions should also occur in the 
interactions of other ABSMs with their parent amyloidogenic peptides and proteins. The 
stabilization of these complexes creates a higher energy barrier to formation of the β-
structured nucleus and thus delays or halts fibril formation. Because ABSM 1a cannot 
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sequester all of the equilibrating Aβ oligomers, the Aβ monomers and oligomers eventually 
succumb to thermodynamics and form Aβ fibrils.
The X-ray crystallographic structure of ABSM 1r may provide insights not only into the 
stabilization of the dimerization and higher-order supramolecular assembly of ABSMs, but 
also into the stabilization and structure of intermediates formed during amyloid aggregation. 
The hydrophobic contacts formed by the Ile, Leu, and Val, at positions 3, 5, and 7 of ABSM 
1r are akin to the steric zipper of amyloidlike fibrils formed by fragments Aβ16–21, Aβ30–35, 
Aβ35–40, and Aβ37–4210, 35. Both the layered crystal structure of ABSM 1r and the 
amyloidlike fibrils are stabilized by hydrophobic contacts. These observations suggest that 
maximization of both hydrophobic contact and hydrogen bonding is key to stabilizing not 
only amyloid fibrils but also transient amyloid oligomers36.
Conclusion
The amyloid β-sheet mimics 1 described herein provide a single platform with which to 
display a variety of amyloidogenic heptapeptide β-strands and provide a rational design for 
inhibitors to control amyloid aggregation. X-ray crystallographic and 1H NMR studies 
validate that the design of ABSMs 1, including the cyclicity, Hao template, two δOrn β-turn 
mimics, and paired side chains, promotes the formation of β-sheets in which the folding is 
largely independent of the amino acid sequence.
ABSMs 1 can be tailored to inhibit aggregation of different amyloid proteins. The inhibition 
of Aβ, hβ2M, and hαSyn1–100 aggregation by ABSMs 1 indicates that ABSMs containing 
one hydrogen-bonding edge and one blocking edge are an effective design for inhibitors of 
amyloid aggregation. The ability of ABSMs 1a, 1m, and 1o to inhibit amyloid aggregation 
and to detoxify amyloid aggregates suggests the potential for therapeutic applications in 
amyloid-related diseases.
Materials and Methods
Synthetic Aβ40 was purchased from GL Biochem (Shanghai) Ltd. Aβ42, hβ2M, and 
hαSyn1–100 were expressed in E. coli. (For details, see the Supplementary Information 
Text.) ABSMs 1 were synthesized as described above. (For details, see the Supplementary 
Information Text.) 1H NMR, 2D TOCSY, and 2D ROESY experiments of ABSMs 1 were 
performed in D2O with DSA as an internal standard at 500 MHz at 298 K. (For details, see 
the Supplementary Information Text.) Crystallization, data collection, and structure 
determination of ABSM 1r are described in the Supplementary Information Text. ThT 
fluorescence assays and TEM studies of Aβ, hβ2M, and hαSyn1–100 aggregation with 
ABSMs 1a, 1m, and 1o are described in the Supplementary Information Text. Cell viability 
assays to establish the toxicity of ABSMs 1a, 1m, and 1o toward HeLa, HEK-293, and 
PC-12 cells are described in the Supplementary Information Text.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Design of amyloid β-sheet mimic 1. (a) Representation of ABSM 1 illustrating the upper β-
strand (recognition β-strand), the δ-linked ornithine (δOrn) turn unit, and the Hao amino acid 
blocker unit. (b) Representation of ABSM 1 recognizing and blocking amyloid aggregation 
through β-sheet interactions.
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Figure 2. 
X-ray crystallographic structure of ABSM 1r, which contains the heptapeptide sequence 
AIIGLMV (Aβ30–36). (a) The monomer. (b) The dimer: top view. (c) The dimer: side view. 
(d) Stacked layers of dimer in the crystal lattice. Note that the view in b is perpendicular to 
the β-sheet (top view), whereas the view in c and d is 90° away, parallel to the β-sheet (side 
view) and shows the hydrophobic contacts. Some side chains in c and d have been omitted 
for clarity.
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Figure 3. 
Effect of ABSMs on inhibition of Aβ40, Aβ42, hβ2M, and hαSyn1–100 aggregation monitored 
by thioflavin T fluorescence assays and transmission electron microscopy. (a) Lag time of 
Aβ40 (20 μM) aggregation in the absence and presence of ABSM 1a. (b) Lag time of Aβ42 
(20 μM) aggregation in the absence and presence of ABSM 1a. (c) Lag time of hβ2M 
(30μM) aggregation in the absence and presence of ABSM 1m. (d) Lag time of hαSyn1–100 
(50μM) aggregation in the absence and presence of ABSM 1o. (e) TEM of Aβ40 (20 μM) 
after incubation for 6 h without ABSM 1a (top) and incubation for 6 h with 1.0 equivalent of 
ABSM 1a (bottom). (f) TEM of Aβ42 (20 μM) after incubation for 7 h without ABSM 1a 
(top) and incubation for 7 h with 1.0 equivalent of ABSM 1a (bottom). (g) TEM of hβ2M 
(30 μM) after incubation for 2 h without ABSM 1m (top) and incubation for 2 h with 1.0 
equivalent of ABSM 1m (bottom). (h) TEM of hαSyn1–100 (50 μM) after incubation for 72 
h without ABSM 1o (top) and incubation for 72 h with 1.0 equivalent of ABSM 1o 
(bottom). * For explanation, see the text and Figures S1, S2, and S4. Error bars correspond 
to standard deviation of four or greater sets of experiments. For experimental details, see the 
Supplementary Information Text.
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Figure 4. 
Effect of ABSM 1a on Aβ40 and Aβ42 toxicity toward PC-12 cells. Addition of Aβ decreases 
cell survival when PC-12 cells are cultured for 24 h with preincubated Aβ. Cell survival 
increases when cells are cultured for 24 h with a preincubated mixture of ABSM 1a and Aβ 
in 0.2, 1.0, and 5 molar ratios. Cell survival is given as a percentage relative to controls in 
which only phosphate-buffered saline (PBS) is added. The cell survival of the PBS controls 
is taken to be 100%. Error bars correspond to standard deviation of four sets of experiments. 
For experimental details, see the Supplementary Information Text.
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Figure 5. 
β-Sheet interactions of Aβ peptides and ABSM 1a. (a) Proposed model of inhibition of Aβ 
aggregation by ABSM 1a. The solid curve corresponds to a pathway in which Aβ aggregates 
without ABSM 1a. The dashed curve corresponds to an alternative pathway in which ABSM 
1a inhibits Aβ aggregation by binding Aβ oligomers. (b) Crystal structure of a macrocyclic 
peptide containing pentapeptide sequence LVFFA17. (PDB ID: 3Q9H) The magenta and 
green structures correspond to parallel and antiparallel β-sheet dimers formed by the 
macrocyclic peptide. The side view shows hydrophobic contacts formed between the 
parallel and antiparallel β-sheet dimers. (c) Crystal structure of the linear peptide 
KLVFFA35. (PDB ID: 3OW9) The orange and purple structures correspond to different 
layers within the crystal structure. The side view shows hydrophobic contacts between the 
layers.
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